Arena Pharmaceuticals, Inc. (ARNA)’s Trend Up, Especially After Today’s Strong Session

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Logo

The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is a huge mover today! The stock increased 3.96% or $2.2 during the last trading session, reaching $57.81. About 567,810 shares traded or 9.37% up from the average. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) has risen 22.67% since June 12, 2018 and is uptrending. It has outperformed by 18.24% the S&P500.
The move comes after 8 months positive chart setup for the $2.87B company. It was reported on Jun, 12 by Barchart.com. We have $60.12 PT which if reached, will make NASDAQ:ARNA worth $114.64 million more.

Analysts await Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) to report earnings on August, 5. They expect $-1.02 EPS, down 56.92 % or $0.37 from last year’s $-0.65 per share. After $12.10 actual EPS reported by Arena Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -108.43 % negative EPS growth.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Ratings Coverage

Among 4 analysts covering Arena Pharmaceuticals (NASDAQ:ARNA), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Arena Pharmaceuticals had 5 analyst reports since December 13, 2018 according to SRatingsIntel. The rating was maintained by Cantor Fitzgerald on Tuesday, February 26 with “Buy”. The stock of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) earned “Outperform” rating by Credit Suisse on Wednesday, April 3. Needham maintained it with “Buy” rating and $60 target in Wednesday, February 27 report.

More notable recent Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) news were published by: Seekingalpha.com which released: “Arena And MannKind Are Associated – Could Something Bigger Happen? – Seeking Alpha” on March 07, 2019, also Seekingalpha.com with their article: “Arena Pharmaceuticals Posts Q3 Loss But Pipeline Is Center Stage – Seeking Alpha” published on November 09, 2018, Nasdaq.com published: “Arena Pharmaceuticals Becomes Oversold (ARNA) – Nasdaq” on March 15, 2018. More interesting news about Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) were released by: Marketwatch.com and their article: “S&P 500, Nasdaq end lower for fourth day after Trump claims China ‘broke the deal’ – MarketWatch” published on May 09, 2019 as well as Nasdaq.com‘s news article titled: “Why Is Arena Pharmaceuticals (ARNA) Down 10.1% Since Last Earnings Report? – Nasdaq” with publication date: March 28, 2019.

Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel small molecule drugs for various therapeutic areas in the United States and Switzerland. The company has market cap of $2.87 billion. The companyÂ’s proprietary investigational clinical programs include etrasimod , which is in Phase IIb evaluation for ulcerative colitis, as well as is in Phase IIa evaluation for dermatologic extraintestinal manifestations in inflammatory bowel disease, pyoderma gangrenosum, and primary biliary cholangitis; ralinepag that is in Phase IIb evaluation to treat pulmonary arterial hypertension; and APD371, which is in Phase IIa evaluation for the treatment of pain associated with Crohn's disease. It has a 4.63 P/E ratio. It has collaboration agreements with Eisai Inc.; Eisai Co., Ltd.; Axovant Sciences Ltd.; and Boehringer Ingelheim International GmbH.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.